Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $4,050 | $4,129 | $3,976 |
| % Growth | – | -1.9% | 3.9% | – |
| Cost of Goods Sold | – | $2,718 | $2,627 | $2,513 |
| Gross Profit | – | $1,332 | $1,503 | $1,463 |
| % Margin | – | 32.9% | 36.4% | 36.8% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $751 | $748 | $665 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $353 | $137 | $147 |
| Operating Expenses | – | $1,104 | $885 | $812 |
| Operating Income | – | $227 | $617 | $651 |
| % Margin | – | 5.6% | 14.9% | 16.4% |
| Other Income/Exp. Net | – | -$134 | -$36 | -$28 |
| Pre-Tax Income | – | $93 | $581 | $623 |
| Tax Expense | – | $68 | $101 | $130 |
| Net Income | – | $10 | $475 | $486 |
| % Margin | – | 0.3% | 11.5% | 12.2% |
| EPS | – | 0.2 | 9.27 | 9.57 |
| % Growth | – | -97.8% | -3.1% | – |
| EPS Diluted | – | 0.2 | 9.22 | 9.48 |
| Weighted Avg Shares Out | – | 51 | 51 | 51 |
| Weighted Avg Shares Out Dil | – | 52 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $9 | $5 | $1 |
| Interest Expense | – | $126 | $137 | $59 |
| Depreciation & Amortization | – | $362 | $314 | $304 |
| EBITDA | – | $581 | $1,032 | $986 |
| % Margin | – | 14.3% | 25% | 24.8% |